EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis

Triple-negativebreast cancer (TNBC) remains the mostchallengingbreast cancer subtype due to its lack of targeted therapies and poorprognosis. In order to treat patients with these tumors, efforts havebeen made to explore feasible targets. Epidermal growth factor receptor(EGFR)-targeted therapy is currently in clinical trials and regardedto be a promising treatment strategy. In this study, an EGFR-targetingnanoliposome (LTL@Rh2@Lipo-GE11) using ginsenoside Rh2 as a wall materialwas developed, in which GE11 was used as the EGFR-binding peptideto deliver more ginsenoside Rh2 and luteolin into TNBC. In comparisonto non-targeted liposomes (Rh2@Lipo and LTL@Rh2@Lipo), the nanoliposomesLTL@Rh2@Lipo-GE11 demonstrated a high specificity to MDA-MB-231 cellsthat expressed a high level of EGFR both in vitro and in vivo, contributingto the strong inhibitory effects on the growth and migration of TNBC.These results suggest that LTL@Rh2@Lipo-GE11 is a prospective candidatefor targeted therapy of TNBC, with a remarkable capability to inhibittumor development and metastasis.